Related references
Note: Only part of the references are listed.A randomized phase II study of palbociclib plus exemestane with GNRH agonist versus capecitabine in premenopausal women with hormone receptor-positive metastatic breast cancer (KCSG-BR 15-10, NCT02592746).
Yeon Hee Park et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Overall Survival with Ribociclib plus Endocrine Therapy in Breast Cancer
S. -A. Im et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Efficacy and safety of fulvestrant in postmenopausal patients with hormone receptor-positive advanced breast cancer: a systematic literature review and meta-analysis
Jiayu Wang et al.
BREAST CANCER RESEARCH AND TREATMENT (2018)
Phase III Randomized Study of Ribociclib and Fulvestrant in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: MONALEESA-3
Dennis J. Slamon et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial
Debu Tripathy et al.
LANCET ONCOLOGY (2018)
Buparlisib plus fulvestrant versus placebo plus fulvestrant for postmenopausal, hormone receptor-positive, human epidermal growth factor receptor 2-negative, advanced breast cancer: Overall survival results from BELLE-2
Mario Campone et al.
EUROPEAN JOURNAL OF CANCER (2018)
Overall Survival with Palbociclib and Fulvestrant in Advanced Breast Cancer
N. C. Turner et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Management of adverse events during cyclin-dependent kinase 4/6 (CDK4/6) inhibitor-based treatment in breast cancer
Marc Thill et al.
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY (2018)
Survival of de novo stage IV breast cancer patients over three decades
Dieter Hoelzel et al.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2017)
MONARCH 2: Abemaciclib in Combination With Fulvestrant in Women With HR+/HER2-Advanced Breast Cancer Who Had Progressed While Receiving Endocrine Therapy
George W. Sledge et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
MONARCH 3: Abemaciclib As Initial Therapy for Advanced Breast Cancer
Matthew P. Goetz et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Systematic review and network meta-analysis comparing palbociclib with chemotherapy agents for the treatment of postmenopausal women with HR-positive and HER2-negative advanced/metastatic breast cancer
Florence R. Wilson et al.
BREAST CANCER RESEARCH AND TREATMENT (2017)
MONARCH 1, A Phase II Study of Abemaciclib, a CDK4 and CDK6 Inhibitor, as a Single Agent, in Patients with Refractory HR+/HER2- Metastatic Breast Cancer
Maura N. Dickler et al.
CLINICAL CANCER RESEARCH (2017)
PALOMA-3: Phase III Trial of Fulvestrant With or Without Palbociclib in Premenopausal and Postmenopausal Women With Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer That Progressed on Prior Endocrine Therapy-Safety and Efficacy in Asian Patients
Hiroji Iwata et al.
JOURNAL OF GLOBAL ONCOLOGY (2017)
Overall survival results from the randomized phase II study of palbociclib (P) in combination with letrozole (L) vs letrozole alone for frontline treatment of ER+/HER2-advanced breast cancer (PALOMA-1; TRIO-18).
Richard S. Finn et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
In real life, one-quarter of patients with hormone receptor-positive metastatic breast cancer receive chemotherapy as initial palliative therapy: a study of the Southeast Netherlands Breast Cancer Consortium
D. J. A. Lobbezoo et al.
ANNALS OF ONCOLOGY (2016)
Mechanistic Investigation of Bone Marrow Suppression Associated with Palbociclib and its Differentiation from Cytotoxic Chemotherapies
Wenyue Hu et al.
CLINICAL CANCER RESEARCH (2016)
Targeting CDK4/6 in patients with cancer
Erika Hamilton et al.
CANCER TREATMENT REVIEWS (2016)
Cytotoxic chemotherapy: Still the mainstay of clinical practice for all subtypes metastatic breast cancer
Chris Twelves et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2016)
Endocrine resistance in hormone-responsive breast cancer: mechanisms and therapeutic strategies
Conleth G. Murphy et al.
ENDOCRINE-RELATED CANCER (2016)
Fulvestrant 500 mg versus anastrozole 1 mg for hormone receptor-positive advanced breast cancer (FALCON): an international, randomised, double-blind, phase 3 trial
John F. R. Robertson et al.
LANCET (2016)
Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial
Massimo Cristofanilli et al.
LANCET ONCOLOGY (2016)
Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer
G. N. Hortobagyi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Palbociclib and Letrozole in Advanced Breast Cancer
Richard S. Finn et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Targeting the RB-E2F pathway in breast cancer
J. Johnson et al.
ONCOGENE (2016)
Targeting the cyclin-dependent kinases (CDK) 4/6 in estrogen receptor-positive breast cancers
Richard S. Finn et al.
BREAST CANCER RESEARCH (2016)
Real-World Treatment Patterns for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer in Europe and the United States
Rita Caldeira et al.
ONCOLOGY AND THERAPY (2016)
Endocrine therapy considerations in postmenopausal patients with hormone receptor positive, human epidermal growth factor receptor type 2 negative advanced breast cancers
Ilenia Migliaccio et al.
BMC MEDICINE (2015)
Fulvestrant 500 mg Versus Anastrozole 1 mg for the First-Line Treatment of Advanced Breast Cancer: Overall Survival Analysis From the Phase II FIRST Study
Matthew J. Ellis et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study
Richard S. Finn et al.
LANCET ONCOLOGY (2015)
Preclinical characterization of the CDK4/6 inhibitor LY2835219: in-vivo cell cycle-dependent/independent anti-tumor activities alone/in combination with gemcitabine
Lawrence M. Gelbert et al.
INVESTIGATIONAL NEW DRUGS (2014)
US Incidence of Breast Cancer Subtypes Defined by Joint Hormone Receptor and HER2 Status
Nadia Howlader et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2014)
Cardiovascular toxicity induced by chemotherapy, targeted agents and radiotherapy: ESMO Clinical Practice Guidelines
G. Curigliano et al.
ANNALS OF ONCOLOGY (2012)
Mechanisms of Endocrine Resistance in Breast Cancer
C. Kent Osborne et al.
ANNUAL REVIEW OF MEDICINE, VOL 62, 2011 (2011)
Recommendations for examining and interpreting funnel plot asymmetry in meta-analyses of randomised controlled trials
Jonathan A. C. Sterne et al.
BMJ-BRITISH MEDICAL JOURNAL (2011)
Epidemiology of breast cancer subtypes in two prospective cohort studies of breast cancer survivors
Marilyn L. Kwan et al.
BREAST CANCER RESEARCH (2009)
Cyclin-dependent kinase pathways as targets for cancer treatment
GI Shapiro
JOURNAL OF CLINICAL ONCOLOGY (2006)
Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer:: Results of a phase III study of the international letrozole breast cancer group
H Mouridsen et al.
JOURNAL OF CLINICAL ONCOLOGY (2001)